In a clinical trial, the efficacy and safety of osimertinib were superior to those of standard EGFR-TKIs in the first-line treatment of NSCLC, suggesting that osimertinib can be used for first-line chemotherapy [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.